scholarly journals Comparative Effects of Preoperative Angiotensin-converting Enzyme In-hibitor, Statin and Beta-blocker Treatment on Human Internal Mammary Artery Reactivity in Patients with Coronary Artery Disease: A Pilot Study

2013 ◽  
Vol 7 (1) ◽  
pp. 69-75 ◽  
Author(s):  
Selvinaz Dalaklioglu ◽  
Ilhan Golbasi ◽  
Caglar Ogutman
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Beta Blocker ◽  
Bypass Surgery ◽  
Internal Mammary Artery ◽  
Ace Inhibitor ◽  
Control Group ◽  
Maximal Effect ◽  
Converting Enzyme ◽  
Significant Difference ◽  
Internal Mammary

Purpose: We investigated the effect of angiotensin-converting enzyme (ACE)- inhibitor, statin, and beta-blocker usage before coronary bypass surgery (CABG) on vascular reactivity of the internal mammary artery (IMA). Methods: Patients, who underwent elective CABG were evaluated. Samples of IMA obtained from 22 patients were divided into 4 groups in respect of drugs used by patients before bypass surgery (control group, ACE inhibitor + statin group, ACE inhibitor + statin + beta-blocker group, and ACE inhibitor + beta-blocker group). The discarded, distal end section of IMA was carefully removed, and the vasoreactivity of IMA rings was evaluated in vitro using an organ chamber. Smooth muscle contractile function was tested on artery segments exposed to 10-80 mM KCl and norepinephrine. The endothelial function of IMA rings was assessed with acetylcholine (ACh) and bradykinin, while endothelium-independent vasorelaxation was evaluated by sodium nitroprusside (SNP). Results: Both ACh and bradykinin caused concentration-dependent relaxation in endothelium-intact IMA rings. However, the maximal effect produced by endothelium-dependent agents in all treatment groups was more prominent when compared with the control group. There was no significant difference in the endothelium-dependent relaxation response of IMA between ACE inhibitor + statin, ACE inhibitor + beta-blocker and ACE inhibitor + statin + beta-blocker groups. The vasodilatory potency of SNP was similar in all groups. Similarly, contractile response to KCl or norepinephrine was not significantly different between groups. Conclusion: Use of ACE inhibitors and statins before bypass surgery may influence IMA vasoreactivity by improving endothelial control of vascular tone.

Angiotensin-Converting Enzyme Gene Polymorphism and Erythropoietin Requirement

2003 ◽  
Vol 23 (2) ◽  
pp. 111-115 ◽  
Author(s):  
Mira Varagunam ◽  
Daniel J. McCloskey ◽  
Paul J. Sinnott ◽  
Martin J. Raftery ◽  
Muhammed M. Yaqoob
Keyword(s):  
Renal Failure ◽  
Parathyroid Hormone ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitor ◽  
Inhibitor Therapy ◽  
Converting Enzyme ◽  
C Reactive Protein ◽  
Dose Requirement ◽  
Reactive Protein ◽  
Significant Difference

Objectives To study the effect of angiotensin-converting enzyme (ACE) polymorphisms II, ID, and DD on erythropoietin (EPO) requirement in patients on continuous ambulatory peritoneal dialysis (CAPD) therapy. Design Retrospective observational study. Setting CAPD Unit, Royal London/St. Bartholomews Hospital, London, UK. Patients 46 patients on the transplant waiting list (age 20 – 70 years), on CAPD therapy for an average of 28 months, seen consecutively over a period of 3 months in the outpatients department. Main Outcome Measures Primary end point: EPO dose requirement in different ACE genotypes. Secondary end points: C-reactive protein, ferritin, parathyroid hormone, Kt/V, duration of dialysis, folate, cause of renal failure, and whether or not patients were on ACE inhibitor therapy. Results There was a statistically significant difference ( p < 0.05) in EPO requirement in the II/ID group compared to the DD group. The mean ± standard error of EPO for the II/ID group was 144 ± 15 U/kg/week, and for the DD group, 87 ± 9 U/kg/ week. The difference in EPO requirement could not be explained by age, C-reactive protein, ferritin, parathyroid hormone, Kt/V, duration of dialysis, folate, cause of renal failure, or whether or not patients were on ACE inhibitor therapy. Conclusion In CAPD patients, ACE genotype has predictive value when determining the EPO dosage, as the II/ID genotype may be associated with a suboptimal response.

GAMBARAN PENGOBATAN PASIEN HIPERTENSI DI PUSKESMAS SEYEGAN SLEMAN YOGYAKARTA PERIODE JANUARI-MARET 2018

2018 ◽  
pp. 1-6
Author(s):  
Agustina Susilowati ◽  
Annisa Meylana Wardani
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Beta Blocker ◽  
Ace Inhibitor ◽  
Channel Blocker ◽  
Converting Enzyme

    Hipertensi adalah suatu kondisi dimana terjadi peningkatan tekanan darah lebih bescar dari 90/140 mmHg. Menurut profil kesehatan kabupaten Sleman (2012) penyakit hipertensi menempati peringkat ke dua dari sepuluh besar penyakit rawat jalan. Tujuan dari penelitian ini adalah mengetahui pola peresepan obat hipertensi dan penggunaan obat antihipertensi secara tunggal dan kombinasi obat pada pasien hipertensi di Puskesmas Seyegan Sleman Yogyakarta periode Januari-Maret 2018.    Jenis penelitian ini yaitu deskriptif non eksperimental dengan pengumpulan data rekam medik pasien hipertensi. Data yang diperoleh dianalisis secara deskriptif yaitu menggambarkan dengan persentase, diagram atau tabel.    Hasil penelitian menunjukkan bahwa pola peresepan obat antihipertensi di Puskesmas Seyegan Sleman Yogyakarta adalah golongan diuretik, Calcium Channel Blocker (CCB), Angiotensin Converting Enzyme (ACE) Inhibitor, Angiotensin Reseptor Blocker (ARB), dan Beta Blocker. Penggunaan obat antihipertensi tunggal yang digunakan adalah golongan CCB 66,67%, ACE Inhibitor 6,41%, dan ARB 1,28%. Sedangkan penggunaan obat antihipertensi untuk kombinasi dua jenis 19,24%, kombinasi tiga jenis 6,40%.    Pola peresepan obat antihipertensi yang digunakan di Puskesmas Seyegan Sleman Yogyakarta adalah golongan diuretik, CCB, ACE Inhibitor, ARB, dan Beta Blocker. Penggunaan obat antihipertensi tunggal yang paling banyak digunakan adalah golongan CCB dan untuk obat kombinasi dua jenis adalah golongan CCB dengan ACE Inhibitor.

scholarly journals Bradykinin Antagonist Counteracts the Acute Effect of Both Angiotensin-Converting Enzyme Inhibition and of Angiotensin Receptor Blockade on the Lower Limit of Autoregulation of Cerebral Blood Flow

2013 ◽  
Vol 34 (3) ◽  
pp. 467-471 ◽  
Author(s):  
Sigurdur T Sigurdsson ◽  
Olaf B Paulson ◽  
Arne Høj Nielsen ◽  
Svend Strandgaard
Keyword(s):  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Angiotensin Converting Enzyme ◽  
Lower Limit ◽  
Ace Inhibitor ◽  
Control Group ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Bradykinin Antagonist ◽  
Hoe 140

The lower limit of autoregulation of cerebral blood flow (CBF) can be modulated with both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB). The influence of bradykinin antagonism on ARB-induced changes was the subject of this study. CBF was measured in Sprague–Dawley rats with laser Doppler technique. The blood pressure was lowered by controlled bleeding. Six groups of rats were studied: a control group and five groups given drugs intravenously: an ACE inhibitor (enalaprilat), an ARB (candesartan), a bradykinin-2 receptor antagonist (Hoe 140), a combination of enalaprilat and Hoe 140, and a combination of candesartan and Hoe 140. In the control group, the lower limit of CBF autoregulation was 54±9 mm Hg (mean±s.d.), with enalaprilat it was 46±6, with candesartan 39±8, with Hoe 140 53±6, with enalaprilat/Hoe 140 52±6, and with candesartan/Hoe 140 50±7. Both enalaprilat and candesartan lowered the lower limit of autoregulation of CBF significantly. The bradykinin antagonist abolished not only the effect of the ACE inhibitor but surprisingly also the effect of the ARB on the lower limit of CBF autoregulation, the latter suggesting an effect on intravascular bradykinin.

scholarly journals Polymorphism of Thyroid Hormones Receptor, Angiotensin-Converting Enzyme, and High Blood Pressure in Childbearing Age Women with Hyperthyroidism

2021 ◽  
Vol 9 (A) ◽  
pp. 387-392
Author(s):  
Agus Wibowo ◽  
Pramudji Hastuti ◽  
Vinayanti Susanti
Keyword(s):  
Blood Pressure ◽  
Angiotensin Converting Enzyme ◽  
Thyroid Hormone Receptor ◽  
Control Group ◽  
Case Group ◽  
Converting Enzyme ◽  
Childbearing Age ◽  
Genotype Frequencies ◽  
Significant Difference ◽  
Childbearing Age Women

AIM: This study aimed to investigate the association between two polymorphisms of thyroid hormone receptor and renin-angiotensin system (THRA C/T and angiotensin-converting enzyme (ACE) I/D) genes with hypertension in childbearing age women with hypertension. METHODS: This was a case–control study including 35 cases and 40 matched control subjects. The case group was hyperthyroid women with hypertension while the control group was hyperthyroid women with normotension. The polymorphisms were identified by a classical polymerase chain reaction. RESULTS: The THRA C/T gene and ACE I/D polymorphisms were not associated with the hypertension while the genotype frequencies in hyperthyroid women with hypertension were as follows: CC genotype was 25.71%, CT genotype was 54.29%, and TT genotype was 20.00%. The ACE I/D genotype frequencies in hyperthyroid women with hypertension were as follows: II genotype was 23.53%, whereas in hyperthyroid women without hypertension, the I/D genotype frequencies were CC: 7.50%, CT: 72.50%, and TT: 20.00%. There were no differences in age, thyroid-stimulating hormone, FT4, systolic blood pressure (SBP), diastolic BP between subgroups in ACE I/D, and at THRA rs-939348. There was a significant difference in the levels of FT4 concentrations in THRA rs-939348. Hypertension groups have higher SBP than controls. Genotype II had higher SBP but it was not statistically significant, while individuals with allele I had SBP higher than D allele. CONCLUSIONS: The I allele of the ACE gene is involved in susceptibility to hypertension and polymorphism in THRA increasing concentration of FT4. There was no statistically significant difference in blood pressure between hyperthyroid women with or without hypertension.

scholarly journals Study of serum angiotensin converting enzyme levels in pemphigus vulgaris

2018 ◽  
Vol 4 (3) ◽  
pp. 328
Author(s):  
V. Anand Kumar ◽  
J. Vijaya Shree
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Pemphigus Vulgaris ◽  
Control Group ◽  
Study Group ◽  
Converting Enzyme ◽  
Serum Angiotensin Converting Enzyme ◽  
Healthy Group ◽  
Significant Difference ◽  
The Mean ◽  
And Control

<p class="abstract"><strong>Background:</strong> This study aimed to evaluate the serum angiotensin converting enzyme (ACE) levels in patients with pemphigus vulgaris compared with healthy volunteers.</p><p class="abstract"><strong>Methods:</strong> In this study, 40 patients were selected in the study group with pemphigus vulgaris and 40 patients were selected in the control group i.e. healthy group. Serum ACE levels were determined by spectrophotometric method.<strong></strong></p><p class="abstract"><strong>Results:</strong> The mean ACE levels in study group and control group were 26.98±15.87 and 32.57±20.98 respectively. There was no statistically significant difference between both the groups (p=0.11). The mean ACE levels were 26.25±12.36 and 26.14±13.89 in females and males respectively in the study group which showed no significant difference (p=0.95). In the control group, the mean ACE levels were 26.22±19.77 and 38.54±11.11 in females and males respectively which showed a statistically significant difference (p=0.04). The mean ACE levels were higher in healthy males when compared to the males in the study group. The mean serum levels in females of both the groups were almost same.</p><p class="abstract"><strong>Conclusions:</strong> The serum ACE level was considerably lower in male study group i.e. pemphigus vulgaris patients compared with male control group i.e. healthy group, despite lack of any significant difference of serum ACE level between pemphigus and control group. Hence, ACE might have some relation with pemphigus vulgaris especially in male patients.</p>

Beneficial effects of carvedilol as a concomitant therapy to angiotensin-converting enzyme inhibitor in patients with ischemic left ventricular systolic dysfunction

2007 ◽  
Vol 85 (2) ◽  
pp. 193-199 ◽  
Author(s):  
Purvi S. Gandhi ◽  
Ramesh K. Goyal ◽  
Anil R. Jain ◽  
B. Srinivas Mallya ◽  
Vishal M. Gupta ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Drug Administration ◽  
Ace Inhibitor ◽  
Systolic Dysfunction ◽  
Left Ventricular ◽  
Control Group ◽  
Converting Enzyme ◽  
Short Term ◽  
Short Term Treatment ◽  
Percent Improvement

Studies are scant on the effects of short-term carvedilol treatment as an adjuvant to angiotensin-converting enzyme (ACE) inhibitor in patients with left ventricular (LV) systolic dysfunction. The objective of this study was to find the effects of short-term treatment of carvedilol on patients with ischemic LV systolic dysfunction (defined as LV ejection fraction (LVEF) ≤30% on 2D echocardiography) undergoing coronary artery bypass surgery (CABG). There were 74 patients that received ACE inhibitor without any β-blocker (control) and 67 patients that received carvedilol in addition to ACE inhibitor following CABG (carvedilol group). After 1 month of drug administration following CABG, the control group was found to have significantly greater percent improvement in LVEF (29.1% ± 5.39%) as compared with the carvedilol group (15.3% ± 4.89%). However, after 3 and 6 months, LVEF levels were found to be significantly greater in the carvedilol group as compared with the control group. Further, at 6 months of drug administration, LV end systolic diameter was significantly less in the carvedilol group (39.11 ± 1.10 mm) as compared with the control group (43.49 ± 1.39 mm). Thus, carvedilol produces beneficial effect on short-term administration in terms of LV contractility when given along with ACE inhibtior as compared with ACE inhibitor therapy alone.

scholarly journals Levels of angiotensin-converting enzyme 1 and 2 in serum and urine of children with Sickle Cell Disease

2021 ◽  
Author(s):  
Ho Chi Hsien ◽  
Dulce Elena Casarini ◽  
João Tomas de Abreu Carvalhaes ◽  
Fernanda Aparecida Ronchi ◽  
Lilian Caroline Gonçalves de Oliveira ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Angiotensin Converting Enzyme ◽  
Glomerular Filtration ◽  
Sickle Cell ◽  
Control Group ◽  
Healthy Children ◽  
Converting Enzyme ◽  
Cell Disease ◽  
Significant Difference ◽  
Ace Activity

Abstract Introduction: Sickle cell nephropathy begins in childhood and presents early increases in glomerular filtration, which, over the long term, can lead to chronic renal failure. Several diseases have increased circulating and urinary angiotensin-converting enzyme (ACE) activity, but there is little information about changes in ACEs activity in children with sickle cell disease (SCD). Objective: We examined circulating and urinary ACE 1 activity in children with SCD. Methods: This cross-sectional study compared children who were carriers of SCD with children who comprised a control group (CG). Serum and urinary activities of ACE were evaluated, as were biochemical factors, urinary album/creatinine rates, and estimated glomerular filtration rate. Results: Urinary ACE activity was significantly higher in patients with SCD than in healthy children (median 0.01; range 0.00-0.07 vs median 0.00; range 0.00-0.01 mU/mL·creatinine, p < 0.001. No significant difference in serum ACE activities between the SCD and CG groups was observed (median 32.25; range 16.2-59.3 vs median 40.9; range 18.0-53.4) mU/m`L·creatinine, p < 0.05. Conclusion: Our data revealed a high urinary ACE 1 activity, different than plasmatic level, in SCD patients suggesting a dissociation between the intrarenal and systemic RAAS. The increase of urinary ACE 1 activity in SCD patients suggests higher levels of Ang II with a predominance of classical RAAS axis, that can induce kidney damage.

scholarly journals Effect of Angiotensin-converting Enzyme Inhibitors on Phenylephrine Responsiveness in Patients with Valvular Heart Disease

2005 ◽  
Vol 33 (2) ◽  
pp. 150-159 ◽  
Author(s):  
HJ Kwak ◽  
YL Kwak ◽  
YJ Oh ◽  
YH Shim ◽  
SH Kim ◽  
...  
Keyword(s):  
Heart Disease ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitors ◽  
Valvular Heart Disease ◽  
Pressor Response ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Control Group ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Significant Difference

We studied patients with valvular heart disease to investigate whether chronic pre-operative treatment with angiotensin-converting enzyme (ACE) inhibitors modulates the effect of phenylephrine (PE) on anaesthesia-induced hypotension. Sixty-five patients were enrolled in the study and hypotension developed after anaesthesia in 36 (18 in the control group and 18 in the ACE inhibitor group). These patients received PE infusions, which were increased in a stepwise fashion at 10-min intervals. Increased mean arterial pressure due to PE infusion was significant only in the control group. There was no significant difference in pressor response or change in haemodynamic variables with PE infusion between the two groups. Treatment with ACE inhibitors did not increase the incidence of hypotensive episodes or significantly modify pressor response after anaesthesia in patients with valvular heart disease.

Sign in / Sign up

Export Citation Format

Share Document